Evaluation of the outcomes of @entity5277 and indications for XXXX .

@entity1 @entity8 @entity29 @entity177 @entity3147 @entity5277
Long-term @entity3147 ( @entity3147 ) and @entity8 ( @entity8 ) are life-saving therapies for @entity1 with @entity5277 ( @entity5277 ). However, indications and timing of these therapies are controversial. In this study we aimed to evaluate the indications for @entity8 . Forty-two @entity1 , each with <100 cm of @entity29 , were divided into three groups according to the length of remnant: group I @entity1 (n = 18): colon plus 50 to 100 cm of @entity29 ( @entity29 ); group II @entity1 (n = 14): colon plus <50 cm of @entity29 ; and group III @entity1 (n = 10): <50 cm of @entity29 without colon. One-year mortality rates for groups I, II, and III were 50%, 72%, and 100%, respectively. All group I survivors developed intestinal adaptation, returning to regular oral feedings at 1 year. Interestingly, three of four surviving @entity1 in group II developed adaptation and were fed an oral short bowel diet (SBD) at 1 year. None of the group III @entity1 survived >1 year, dying due to @entity177 in the early postoperative period or from sepsis within 1 year. We conclude that @entity1 with a very short bowel are candidates for @entity8 when stable. If the colon is intact, however, regardless of @entity29 remnant length, the @entity1 should be given a chance to develop intestinal adaptation before making the decision for permanent @entity3147 or @entity8 .
